FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Glenmark Life Sciences IPO is a book built issue of Rs 1,513.60 crores. The issue comprises of fresh issue of Rs 1,060.00 crore and offer for sale of 0.63 crore shares.
Glenmark Life Sciences IPO bidding started from July 27, 2021 and ended on July 29, 2021. The allotment for Glenmark Life Sciences IPO was finalized on Tuesday, August 3, 2021. The shares got listed on BSE, NSE on August 6, 2021.
Glenmark Life Sciences IPO price band is set at ₹695 to ₹720 per share. The minimum lot size for an application is 20 Shares. The minimum amount of investment required by retail investors is ₹14,400.
Bofa Securities India Limited, Bob Capital Markets Limited, Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited and SBI Capital Markets Limited are the book running lead managers of the Glenmark Life Sciences IPO, while Kfin Technologies Limited is the registrar for the issue.
Refer to Glenmark Life Sciences IPO RHP for detailed information.
| IPO Date | July 27, 2021 to July 29, 2021 |
| Listing Date | August 6, 2021 |
| Face Value | ₹2 per share |
| Price Band | ₹695 to ₹720 per share |
| Lot Size | 20 Shares |
| Total Issue Size | [.] shares (aggregating up to ₹1,513.60 Cr) |
| Fresh Issue | [.] shares (aggregating up to ₹1,060.00 Cr) |
| Offer for Sale | 6,300,000 shares of ₹2 (aggregating up to ₹453.60 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Glenmark Life Sciences IPO offers 15,018,279 shares. 4,242,379 (28.25%) to QIB, 3,232,770 (21.53%) to NII, 7,543,130 (50.23%) to RII. 377,156 RIIs will receive minimum 20 shares and (sNII) and (bNII) will receive minimum 280 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | - | NA |
| QIB Shares Offered | 4,242,379 (28.25%) | NA |
| NII (HNI) Shares Offered | 3,232,770 (21.53%) | |
| Retail Shares Offered | 7,543,130 (50.23%) | 377,156 |
| Total Shares Offered | 15,018,279 (100%) |
Glenmark Life Sciences IPO opens on July 27, 2021, and closes on July 29, 2021.
| IPO Open Date | Tuesday, July 27, 2021 |
| IPO Close Date | Thursday, July 29, 2021 |
| Basis of Allotment | Tuesday, August 3, 2021 |
| Initiation of Refunds | Wednesday, August 4, 2021 |
| Credit of Shares to Demat | Thursday, August 5, 2021 |
| Listing Date | Friday, August 6, 2021 |
| Cut-off time for UPI mandate confirmation | 5 PM on July 29, 2021 |
Investors can bid for a minimum of 20 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,400 |
| Retail (Max) | 13 | 260 | ₹187,200 |
| Lot Size Calculator | |||
Glenmark Pharmaceuticals Limited is the promoter of the company.
| Share Holding Pre Issue | 100% |
| Share Holding Post Issue | 82.84% |
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
| Particulars | For the year/period ended (₹ in million) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 19,970.75 | 17,256.04 | 14,753.95 | ||
| Total Revenue | 18,859.76 | 15,493.03 | 8,868.65 | ||
| Profit After Tax | 3,515.81 | 3,130.98 | 1,955.92 | ||
[Dilip Davda] Though this is a second public issue from Glenmark group after nearly two decades, it is encasing on the fancy of pharma segment amidst pandemic and hence the issue is fully priced discounting all near term positives. Considering the group's credentials and ongoing grey market activities the IPO may evoke a good response. Cash surplus investors may consider investing in this offer with a long term perspective. Read detail review...
The Glenmark Life Sciences IPO is subscribed 44.17 times on July 29, 2021 5:01:00 PM. The public issue subscribed 14.63 times in the retail category, 36.97 times in the QIB category, and 122.54 times in the NII category. Check Day by Day Subscription Details (Live Status)
Application Wise IPO Subscription (Retail): 10.74 times
| Category | Subscription (times) |
|---|---|
| QIB | 36.97 |
| NII | 122.54 |
| Retail | 14.63 |
| Total | 44.17 |
| Listing Date | August 6, 2021 |
| BSE Script Code | 543322 |
| NSE Symbol | GLS |
| ISIN | INE03Q201024 |
| Final Issue Price | ₹720 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹720.00 |
| ₹751.10 |
| ₹737.35 |
| ₹799.95 |
| ₹748.20 |
| NSE |
|---|
| ₹720.00 |
| ₹750.00 |
| ₹738.00 |
| ₹799.00 |
| ₹748.50 |
Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,
Phone: +91 2189 234456/ +91 2189
Email: complianceofficer@glenmarklifesciences.com
Website: http://www.glenmarklifesciences.com/
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: glenmark.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Lead Manager Reports
Glenmark Life Sciences IPO is a main-board IPO of [.] equity shares of the face value of ₹2 aggregating up to ₹1,513.60 Crores. The issue is priced at ₹695 to ₹720 per share. The minimum order quantity is 20 Shares.
The IPO opens on July 27, 2021, and closes on July 29, 2021.
Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Glenmark Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Glenmark Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Glenmark Life Sciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Glenmark Life Sciences IPO opens on July 27, 2021 and closes on July 29, 2021.
Glenmark Life Sciences IPO lot size is 20 Shares, and the minimum amount required is ₹14,400.
You can apply in Glenmark Life Sciences IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Glenmark Life Sciences IPO will be done on Tuesday, August 3, 2021, and the allotted shares will be credited to your demat account by Thursday, August 5, 2021. Check the Glenmark Life Sciences IPO allotment status.
Useful Articles
FREE Account Opening (₹0)
FREE Intraday Trading (Eq, F&O)
|
|
RHP
IPO Mentor (700+ Posts, 500+ Likes)
IPO Guru (1800+ Posts, 1600+ Likes)
Top Contributor (200+ Posts, 100+ Likes)
